Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT03953820Phase 2Completed
Phase 2, randomised, open-label trial of libervant in epilepsy (3 arms), sponsored by Aquestive Therapeutics. Primary endpoints: Area Under the Curve from time 0 to time t at 240 hours, Area Under the Curve from time 0 to infinity at 240 hours and 1 more. Started Apr 2019; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT03953820.